Search

Displaying results 1041 - 1050 of 2872 in total
  1. Drug

    PF-04217903

    go.drugbank.com/drugs/DB12848
    Investigational

    PF-04217903 has been used in trials studying the treatment of Neoplasms.

  2. Drug

    PI-103

    go.drugbank.com/drugs/DB17046
    Experimental

    PI-103 is an inhibitor of p110α of class I PI3K.[A253092]

  3. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.

  4. Drug

    Gavestinel

    go.drugbank.com/drugs/DB06741
    Experimental

    Gavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is orally bioavailable and active in vivo.

  5. Drug

    PF-06273340

    go.drugbank.com/drugs/DB12269
    Investigational

    Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects

  6. Drug

    Omeprazole

    go.drugbank.com/drugs/DB00338
    ApprovedInvestigationalVet approved

    Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases cha...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: OMEPRAZOLO P-CARE, NANSEN
  7. Drug

    PF-03814735

    go.drugbank.com/drugs/DB13059
    Investigational

    PF-03814735 has been used in trials studying the treatment of Solid Tumors.

  8. Drug

    Albutrepenonacog alfa

    go.drugbank.com/drugs/DB13884
    Approved

    Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin). It was developed by CSL Behring Canada, Inc and approved by Health Canada ...

  9. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.

  10. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.